Anzeige
Erschienen in:
01.05.2005 | Oral presentation
Efficacy of high-dose alkylating chemotherapy in the adjuvant treatment of HER2/neu-negative primary breast cancer: update of the Dutch randomized trial
Erschienen in: Breast Cancer Research | Sonderheft 1/2005
Einloggen, um Zugang zu erhaltenExcerpt
The role of high-dose chemotherapy in the adjuvant treatment of high-dose breast cancer has not been established. Results have been reported from six randomized studies with a symmetrical study design (Table 1). All show a lower relapse rate in the high-dose arm, but in only one study was this result statistically significant.
Table 1
Randomized studies evaluating the role of high-dose chemotherapy in high-risk breast cancer
|
Author
|
Patients
|
Selection
|
Conventional arm
|
High-dose arm
|
RFS analysis
|
|---|---|---|---|---|---|
|
Rodenhuis [1]
|
885
|
4+ nodes
|
5×FEC
|
4×FEC - CTC
|
HD better (P = 0.08)
|
|
Peters [2]
|
785
|
10+ nodes
|
4×CAF + ID-CPB
|
4×CAF + HD-CPB
|
No difference, HD fewer relapses
|
|
Tallman [3]
|
540
|
10+ nodes
|
6×CAF
|
6×CAF + CT
|
No difference, HD fewer relapses
|
|
Roché
|
314
|
8+ nodes
|
4×FEC
|
4×FEC + CMA
|
HD better (P = 0.002)
|
|
Tokuda
|
97
|
10+ nodes
|
6×CAF
|
6×CAF + CT
|
HD better (NS)
|
|
Rodenhuis
|
81
|
Infraclav biopsy
|
4×FEC
|
4×FEC + CTC
|
No difference, HD less relapses
|